CN110964747A - 胶质瘤细胞中高效特异表达的自杀基因腺病毒及构建方法 - Google Patents
胶质瘤细胞中高效特异表达的自杀基因腺病毒及构建方法 Download PDFInfo
- Publication number
- CN110964747A CN110964747A CN201911171025.7A CN201911171025A CN110964747A CN 110964747 A CN110964747 A CN 110964747A CN 201911171025 A CN201911171025 A CN 201911171025A CN 110964747 A CN110964747 A CN 110964747A
- Authority
- CN
- China
- Prior art keywords
- adenovirus
- mir
- recombinant expression
- pgl4
- fos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 80
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 56
- 206010018338 Glioma Diseases 0.000 title claims abstract description 54
- 208000032612 Glial tumor Diseases 0.000 title claims abstract description 53
- 230000014509 gene expression Effects 0.000 title claims abstract description 45
- 238000010276 construction Methods 0.000 title abstract description 6
- 239000013604 expression vector Substances 0.000 claims abstract description 81
- 238000003259 recombinant expression Methods 0.000 claims abstract description 68
- 108091070946 miR-128 stem-loop Proteins 0.000 claims abstract description 58
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 claims abstract description 46
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 claims abstract description 45
- 230000000295 complement effect Effects 0.000 claims abstract description 38
- 241000700605 Viruses Species 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 31
- 239000012634 fragment Substances 0.000 claims abstract description 23
- 108700025906 fos Genes Proteins 0.000 claims abstract description 13
- 238000000746 purification Methods 0.000 claims abstract description 11
- 239000006228 supernatant Substances 0.000 claims abstract description 9
- 230000035897 transcription Effects 0.000 claims description 23
- 238000013518 transcription Methods 0.000 claims description 23
- 238000010367 cloning Methods 0.000 claims description 15
- 108060001084 Luciferase Proteins 0.000 claims description 11
- 239000005089 Luciferase Substances 0.000 claims description 11
- 108091030146 MiRBase Proteins 0.000 claims description 5
- 239000003623 enhancer Substances 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 3
- 241000700584 Simplexvirus Species 0.000 claims description 3
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 3
- 108020004440 Thymidine kinase Proteins 0.000 claims description 3
- 239000005090 green fluorescent protein Substances 0.000 claims description 3
- 238000002372 labelling Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 16
- 230000008685 targeting Effects 0.000 abstract description 4
- 230000002950 deficient Effects 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 62
- 206010028980 Neoplasm Diseases 0.000 description 17
- 210000004498 neuroglial cell Anatomy 0.000 description 13
- 239000013598 vector Substances 0.000 description 11
- 238000001415 gene therapy Methods 0.000 description 10
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 9
- 229960002963 ganciclovir Drugs 0.000 description 9
- 230000002103 transcriptional effect Effects 0.000 description 8
- 101000904152 Homo sapiens Transcription factor E2F1 Proteins 0.000 description 5
- 101150000187 PTGS2 gene Proteins 0.000 description 5
- 102000000763 Survivin Human genes 0.000 description 5
- 108010002687 Survivin Proteins 0.000 description 5
- 102100024026 Transcription factor E2F1 Human genes 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 201000007983 brain glioma Diseases 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 102100027584 Protein c-Fos Human genes 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 108010017842 Telomerase Proteins 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 230000005758 transcription activity Effects 0.000 description 2
- 101150071146 COX2 gene Proteins 0.000 description 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 230000035519 G0 Phase Effects 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 206010061311 nervous system neoplasm Diseases 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
- C12N9/1211—Thymidine kinase (2.7.1.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
- C12Y207/01021—Thymidine kinase (2.7.1.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
一种胶质瘤细胞中高效特异表达的自杀基因腺病毒及构建方法，其特征在于，腺病毒通过下述方法构建，使用PCR方法克隆c‑fos基因启动子片段，将其连接到腺病毒表达载体上，在c‑fos启动子下游连接自杀基因及miR‑128互补序列，构建出腺病毒重组表达载体；将腺病毒重组表达载体转染293细胞，待细胞有出毒迹象时，收集病毒上清，利用病毒上清将病毒扩增至P3代，其后用腺病毒纯化试剂盒纯化病毒。本发明通过将miR‑128互补序列放在自杀基因的下游，正常细胞高表达miR‑128，而miR‑128互补序列可沉默miR‑128表达的目的，从而可对自杀基因在正常细胞中的表达发挥抑制效果，而胶质瘤细胞中miR‑128表达缺失，自杀基因可以在胶质瘤细胞中大量转录，从而能够进一步提高自杀基因在胶质瘤细胞中的靶向性，实现了自杀基因在胶质瘤细胞中高效且特性性的表达。
Description
【技术领域】
本发明涉及生物医学领域，特别涉及一种胶质瘤细胞中高效特异表达的自杀基因腺病毒及构建方法。
【背景技术】
神经系统的肿瘤中，胶质瘤的恶性程度是最高的，发病人群主要集中在30-40岁之间的成人及10-20岁之间的青少年。目前，临床对胶质瘤的标准治疗包括手术切除、放疗及化疗。在成人中，患者手术后联合放化、疗的中位生存期只有14.6个月；一部分儿童患者，3年生存率低于20％。脑胶质瘤预后差，严重危害人民生命安全。其浸润性生长特点，与正常脑组织无明显界限，并向周围正常脑组织呈指状浸润破坏，导致传统的治疗方法如手术切除、放疗、化疗等均很难将其根除。近年来，基因治疗被广泛应用于多种肿瘤的治疗研究，为脑胶质瘤的治疗带来曙光。
目前，自杀基因治疗策略已被广泛应用于肿瘤基因治疗研究，具有潜在的重大临床应用价值。单纯疱疹病毒胸苷激酶(herpes simplex virus-thymidine kinase,HSV-TK)基因是肿瘤基因治疗应用最广泛的自杀基因。单纯疱疹病毒胸苷激酶能将一些对哺乳动物细胞无毒性的核苷类似物转化成有毒性的磷酸化物，阻止细胞DNA的正常合成。当HSV-TK基因被导入肿瘤细胞后，联合应用更昔洛韦(ganciclovir,GCV)不仅能杀灭转染的肿瘤细胞，并且能通过旁观者效应杀伤周围没有转染的肿瘤细胞。迄今为止，采用HSV-TK基因转染联合GCV的“自杀基因”疗法已在卵巢癌、恶性黑色素瘤等人类实体细胞肿瘤治疗实验中取得了较好的效果。
自杀基因在肿瘤细胞中高效、特异性的表达对基因治疗的有效性和安全性有着极其重要的影响，也是目前基因治疗所面临的巨大挑战之一。开发和利用肿瘤特异性启动子为解决这一问题提供了一种可行的途径。近年来，已知的可作为肿瘤研究的特异性启动子主要有端粒酶(Tert)启动子、甲胎蛋白(AFP)启动子、癌胚抗原(CEA)启动子以及前列腺特异性抗原启动子等。
虽然目前基于这些肿瘤或组织特异性启动子的靶向基因治疗已经取得了一定的疗效，但由于肿瘤特异性启动子在正常细胞中仍然有少量的表达，限制了基因治疗的给药剂量，为了保障安全，不得不延长给药间隔时间，从而明显降低了基因治疗的疗效。另外，启动子也可能会因体内信号传导的复杂性而逐渐失去活性。因此，为了实现基因治疗早日进入临床试验，需继续寻求更安全、更有效的策略以及高效、靶向性的方法表达自杀基因，从而高效发挥抗胶质瘤的作用。
经过长期研究发现，c-fos启动子在脑胶质瘤中具有较高的转录活性，其相比于其他启动子，具有更好的肿瘤选择性。C-fos是编码核蛋白的一个重要的癌基因，定位于染色体14q23.4，其产物由380个氨基酸残基组成。C-fos基因具有独特的表达特性，表现为在细胞增殖周期的静止期(G0期)基本不表达，而多在细胞周期的(G0～G1)期表达。C-fos癌蛋白在肿瘤细胞核内发挥着重要的作用，可以与Jun蛋白形成异二聚体构成AP-1，Fos蛋白通过使Jun蛋白C末端的磷酸化从而活化AP-1的转录因子活性，进而刺激核内其他细胞增值有关基因的转录，促使细胞由G0期启动而进入细胞增殖周期，导致细胞癌变。研究已经表明，c-fos癌基因与肿瘤的发生发展和预后有关，在胃癌、胶质瘤、宫颈癌、皮肤鳞状细胞癌、子宫内膜癌等肿瘤中c-fos蛋白的表达均有显著增加。在我们前期的研究当中也发现了类似的现象，我们克隆了c-fos基因编码区上游600bp的启动子片段，插入在pGL4载体上，通过其他广泛研究的肿瘤特异性启动子，包括端粒酶(Tert)启动子，Survivin启动子、Cox2启动子、E2F1启动子比较发现：c-fos启动子驱动下的荧光素酶报告基因在胶质瘤细胞系中的转录水平显著高于上述启动子。进一步的动物实验发现，与没有肿瘤选择性的CMV启动子相比，c-fos启动子在正常组织转录活性较低，具有比较高的安全性。
虽然，c-fos启动子在正常组织转录活性较低，但其在正常细胞中(主要是脑胶质细胞，神经元细胞)仍有一定的转录活性，这样就不可避免的出现自杀基因在正常细胞表达，造成毒副作用。
与本发明相关的现有技术有如下参考文献：
1.Kesari S.Understanding glioblastoma tumor biology:the potential toimprove current diagnosis and treatments.Semin Oncol.2011,38:S2-10.
2.Broniscer A,Chintagumpala M,Fouladi M,et al.Temozolomide afterradiotherapy for newly diagnosed high-grade glioma and unfavorable low-gradeglioma in children.J Neurooncol,2006,76(3):313-319.
3.Tobias A,Ahmed A,Moon KS,et al.The art of gene therapy for glioma:areview of the challenging road to the bedside.J Neurol Neurosurg Psychiatry,2013,84(2):213-222.
4.Aboody KS,Brown A,Rainov NG,et al.Neural stem cells displayextensive tropism for pathology in adult brain:evidence from intracranialgliomas.Proc Natl Acad Sci USA,2000,97(23):12846-12851.
5.Gambini E,Reisoli E,Appolloni I,et al.eplication-competent herpessimplex virus retargeted to HER2 as therapy for high-grade glioma.Mol Ther,2012,20(5):994-1001.
6.Sampson JH,Archer GE,Mitchell DA,et al.An epidermal growth Factorreceptor variant III-targeted vaccine is safe and immunogenic in patientswith glioblastoma multiforme.Mol Cancer Ther,2009,8(10):2773-2779.
7.Schartner JM,Hagar AR,Van Handel M,et al.Impaired capacity forupregulation of MHC class II in tumor-associated microglia.Glia,2005,51(4):279-285.
8.Sathornsumetee S,Rich JN,Reardon DA.Diagnosis and treatment ofhigh-grade astrocytoma.Neurol Clin,2007,25(4):1111-1139.
9.Partap S,Fisher PC.Update on new treatments and developments inchildhood brain tumors.Curt Opin Pediatr,2007,19(6):670-674.
10.Cao G,Kuriyama S,Gao J,et al.Gene therapy for hepatocellularcarcinoma based on tumour-selective suicide gene expression using the alpha-fetoprotein(AFP)enhancer and a housekeeping gene promoter.Eur J Cancer,2001,37(1):140-147.
11.Xie X,Li L,Xiao X,et al.Targeted expression of BikDD eliminateseliminates breast cancer with virtually no toxicity in noninvasive imagingmodels.Mol Cancer Ther,2012,11(9):1915-1924.
12.Shao R,Lee DF,Wen Y,et al.E1A sensitizes cancer cells to TRAILinduced apoptosis through enhancement of caspase activation.Mol Cancer Res,2005,3(4):219-226.
13.Yip KW,Reed JC.Bcl-2family proteins and cancer.Oncogene,2008,27(50):6398-6406.
14.JENSEN RL.Brain tumor hypoxia:tumorigenesis,angiogenesis,imaging,pseudoprogresion,and as a therapeutic target.J Neurooncol,2009,92(3):317-335.
15.N.Varda-Bloom,I.Hodish,A.Shaish.Specific Induction of TumorNeovasculature Death by Modified Murine PPE-1Promoter Armed with HSV-TK.Pathobiology,2008,75(6):346-355.
16.Zhang L,Li XW,Zhao MW,et al.Antisense oligonucleotide targeting c-fos mRNA limits retinal pigment epithelial cell proliferationL a key step inthe progression of proliferative vitreoretinopathy.Exp Eye Res,2006,83(6):1405-1411.
17.赵文娟,于士柱,浦佩玉,等.胶质瘤细胞c-fos基因表达水平对其增殖和凋亡的影响.中国现代神经疾病杂志,2007,7(2):141-145.
18.Bi JX,Buhr P,Zeng AP,et al.Human c-fos promoter mediates high-level,inducible expression in various mammalian cell lines.Biotechnol Bioeng,2003,81(7):848–854.
19.Tsai WC,Hsu SD,Hsu CS,et al.MicroRNA-122plays a critical role inliver homeostasis and hepatocarcinogenesis.J Clin Invest,2012,122(8):2884-2897.
20.Png KJ,Halberg N,Yoshida M,et al.A microRNA regulon that mediatesendothelial recruitment and metastasis by cancer cells.Nature,2012,481(7380):190-194.
21.Wang CM,Wang Y,Fan CG,et al.miR-29c targets TNFAIP3,inhibits cellproliferation and induces apoptosis in hepatitis B virus-relatedhepatocellular carcinoma.Biochem Biophys Res Commun,2011,411(3):586-592.
22.Card PB,Hogg RT,Gil DAC,et al.MicroRNA silencing improves thetumor specificity of adenoviral transgene expression.Cancer Gene Ther,2012,19(7):451-459.
23.Wu C,Lin J,Hong M,et al.Combinatorial control of suicide geneexpression by tissue-specific promoter and microRNA regulation for cancertherapy.Mol Ther,2009,17(12):2058-2066.
24.Ciafre SA,Galardi S,Mangiola A,et al.Extensive modulation of a setof microRNAs in primary glioblastoma.Biochem Biophys Res Commun,2005,334(4):1351-8.
25.Zhang Y,Chao T,Li R,et al.MicroRNA-128inhibits glioma cellsproliferation by targeting transcription factor E2F3a.J Mol Med,2009,87(1):43-51.
【发明内容】
本发明旨在解决上述问题，而提供一种在胶质瘤细胞中高效特异表达的自杀基因腺病毒，使得自杀基因可在胶质瘤细胞中高效表达，在正常细胞中不表达，从而避免自杀基因对正常细胞造成毒副作用，提高安全性。此外，还提供一种该腺病毒的构建方法。
为实现上述目的，本发明提供了一种胶质瘤细胞中高效特异表达的自杀基因腺病毒，其特征在于，该腺病毒基因组中包含有c-fos启动子、自杀基因和在正常细胞高表达并在胶质瘤细胞中表达确实的miR-128的互补序列，所述自杀基因位于所述c-fos启动子的下游，所述miR-128的互补序列位于所述自杀基因的下游。
进一步地，所述腺病毒通过下述方法构建：
使用PCR方法克隆c-fos基因启动子片段，将其连接到腺病毒表达载体上，在c-fos启动子下游连接自杀基因及miR-128的互补序列，构建出腺病毒重组表达载体；将腺病毒重组表达载体转染293细胞，待细胞有出毒迹象时，收集病毒上清，并将病毒扩增至P3代，其后用腺病毒纯化试剂盒纯化病毒，以获得所述腺病毒。
进一步地，所述自杀基因为单纯疱疹病毒胸苷激酶HSV-TK，所述腺病毒表达载体为pDC315。
进一步地，所述腺病毒纯化试剂盒选用ViraBind腺病毒纯化试剂盒。
进一步地，所述miR-128的互补序列通过以下方法确定：
使用PCR方法克隆不同片段长度的c-fos启动子片段，设计CMV增强子(IE)序列，优化启动子与多克隆位点(MCS)及表达框(ORF)的距离，设计出高效转录表达的表达框；
将表达框连接到pGL4表达载体上，克隆出pGL4-cfos重组表达载体；
通过miRBase数据库，设计若干条序列不同的miR-128的互补序列，并将其分别串联到pGL4-cfos重组表达载体的3’末端，构建出若干种序列不同的pGL4-cfos-miR128重组表达载体；
利用外源荧光素酶法检测各pGL4-cfos-miR128重组表达载体中的c-fos启动子在胶质瘤细胞和正常细胞中的转录水平，筛选出在胶质瘤细胞中具有较高转录水平而在正常细胞中具有较低转录水平的pGL4-cfos-miR128重组表达载体，将该pGL4-cfos-miR128重组表达载体所对应的miR-128的互补序列作为构建腺病毒重组表达载体所需的miR-128的互补序列。
此外，本发明还提供一种腺病毒的构建方法，其包括以下步骤：
使用PCR方法克隆c-fos基因启动子片段，将其连接到腺病毒表达载体Pdc315上；
在c-fos启动子下游连接自杀基因及miR-128的互补序列，构建出腺病毒重组表达载体；
将腺病毒重组表达载体转染293细胞，待细胞有出毒迹象时，收集病毒上清，并将病毒扩增至P3代，其后用腺病毒纯化试剂盒纯化病毒，以获得所述腺病毒。
进一步地，在c-fos启动子下游连接自杀基因及miR-128的互补序列，构建出腺病毒重组表达载体时，其还可将用于标记的绿色荧光蛋白基因GFP连接在c-fos启动子下游。
进一步地，所述miR-128的互补序列通过以下方法确定：
使用PCR方法克隆不同片段长度的c-fos启动子片段，设计CMV增强子(IE)序列，优化启动子与多克隆位点(MCS)及表达框(ORF)的距离，设计出高效转录表达的表达框；
将表达框连接到pGL4表达载体上，克隆出pGL4-cfos重组表达载体；
通过miRBase数据库，设计若干条序列不同的miR-128的互补序列，并将其分别串联到pGL4-cfos重组表达载体的3’末端，构建出若干种序列不同的pGL4-cfos-miR128重组表达载体；
利用外源荧光素酶法检测各pGL4-cfos-miR128重组表达载体中的c-fos启动子在胶质瘤细胞和正常细胞中的转录水平，筛选出在胶质瘤细胞中具有较高转录水平而在正常细胞中具有较低转录水平的pGL4-cfos-miR128重组表达载体，将该pGL4-cfos-miR128重组表达载体所对应的miR-128的互补序列作为构建腺病毒重组表达载体所需的miR-128的互补序列。
本发明的有益贡献在于，其有效解决了上述问题。本发明通过将miR-128互补序列放在自杀基因的下游，正常细胞高表达miR-128，而miR-128互补序列可沉默miR-128表达的目的，从而可对自杀基因在正常细胞中的表达发挥抑制效果，而胶质瘤细胞中miR-128表达缺失，自杀基因可以在胶质瘤细胞中大量转录，从而能够进一步提高自杀基因在胶质瘤细胞中的靶向性。本发明利用在胶质瘤中有特异性的c-fos启动子驱动自杀基因高水平的表达，同时将microRNA调节机制整合到转录靶向性载体中，相当于为预防自杀基因在非肿瘤组织中的表达上了一道"双保险"，从而实现了自杀基因在胶质瘤细胞中高效且特性性的表达。
【附图说明】
图1肿瘤特异性启动子C-fos、hTERT、Survivin、E2F1、Cox2的pGL4载体：pGL4-cfos、pGL4-TERT、pGL4-Survivin、pGL4-E2F1、pGL4-Cox2重组表达载体的示意图。
图2是pGL4-CMV、pGL4-Tert、pGL4-Survivin、pGL4-E2F1、pGL4-Cox2、pGL4-Vector、pGL4-cfos重组表达载体在胶质瘤细胞中的荧光素酶表达活性检测结果；其中，横坐标表征各重组表达载体，纵坐标表征荧光素酶的表达活性。
图3是pDC315-CFOS-TK-IRES-hrGFP和pDC315-CMV-TK-IRES-hrGFP分别感染胶质瘤细胞系U373的荧光图像。
图4是c-fos/HSV-TK/miR-128腺病毒和CMV/HSV-TK/miR-128腺病毒对U87、U251、U373及正常胶质细胞的杀伤实验结果，其中，横坐标为前体药物更昔洛韦GCV的浓度，纵坐标为细胞存活率。
图5是C-fos和CMV启动子在小鼠体内的转录活性比较分析
【具体实施方式】
下列实施例是对本发明的进一步解释和补充，对本发明不构成任何限制。
一、优化c-fos启动子，并验证c-fos启动子在胶质瘤细胞中的表达效率及特异性：
首先通过PCR方法克隆不同片段长度的c-fos基因启动子片段，设计CMV增强子(IE)序列，优化启动子与多克隆位点(MCS)和表达框(ORF)的距离，设计出高效转录表达的表达框。经测序验证后，将c-fos启动子片段插入到荧光素酶报告基因——pGL4表达载体上，克隆出pGL4-cfos重组表达载体。
作为对比，以相同或相似的方法分别构建出肿瘤特异性启动子CMV、Tert、Survivin、Cox2、E2F1、Vector的pGL4载体：pGL4-CMV重组表达载体、pGL4-Tert重组表达载体、pGL4-Survivin重组表达载体、pGL4-Cox2重组表达载体、pGL4-E2F1重组表达载体、pGL4-Vector重组表达载体(如图1所示)。
其后，将pGL4-CMV重组表达载体、pGL4-Tert重组表达载体、pGL4-Survivin重组表达载体、pGL4-E2F1重组表达载体、pGL4-Cox2重组表达载体、pGL4-Vector重组表达载体、pGL4-cfos重组表达载体分别转入胶质瘤细胞株U87、U251、U373中，并检测荧光素酶的表达活性。如图2所示，通过检测，我们发现c-fos启动子在胶质瘤细胞中的转录活性仅次于CMV启动子，高于Tert、Survivin、E2F1、Cox2、Vector等启动子。
二、c-fos启动子在小鼠体内的转录活性验证
两组小鼠分别以公知方法注射pGL4-CMV重组表达载体和pGL4-cfos重组表达载体。24h后分别取小鼠心、肝、脾、肺、肾进行荧光素酶活性检测，其检测结果如图5所示。
从图5中可以看出，c-fos启动子在小鼠主要脏器中的转录活性远低于CMV启动子。
三、确定microRNA-128互补序列
通过miRBase数据库，设计若干条miR-128的互补序列，将其分别串联到pGL4-cfos重组表达载体的3’末端，构建出若干种具有不同miR-128互补序列的pGL4-cfos-miR128重组表达载体；
利用外源荧光素酶法检测各pGL4-cfos-miR128重组表达载体中的c-fos启动子在胶质瘤细胞和正常细胞(胶质细胞、神经元细胞)中的转录水平，筛选出在胶质瘤细胞中具有较高转录水平而在正常细胞中具有较低转录水平的pGL4-cfos-miR128重组表达载体，以该pGL4-cfos-miR128重组表达载体所对应的miR-128的互补序列作为最优的miR-128互补序列。
四、c-fos/HSV-TK/miR-128自杀基因重组腺病毒载体的制备和病毒包装
使用PCR方法克隆c-fos基因启动子片段，将其连接到腺病毒表达载体pDC315上，在c-fos启动子下游连接自杀基因HSV-TK、miR-128互补序列和用于标记的绿色荧光蛋白基因GFP，构建出包含自杀基因HSV-TK的腺病毒重组表达载体pDC315-CFOS-TK-IRES-hrGFP；
将腺病毒重组表达载体pDC315-CFOS-TK-IRES-hrGFP转染HEK293细胞，待细胞有出毒迹象时，收集病毒上清。将病毒扩增至P3代，其后用ViraBind腺病毒纯化试剂盒纯化病毒，获得纯化浓缩的c-fos/HSV-TK/miR-128腺病毒。
五、c-fos/HSV-TK/miR-128自杀基因重组腺病毒的高效特性表达的验证
通过病毒扩增法使c-fos/HSV-TK/miR-128腺病毒的滴度达到1×10^10PFU/ML；
以不同感染复数(MOI：100,10，1)的c-fos/HSV-TK/miR-128腺病毒分别加入到胶质瘤细胞系U87、U251、U373及正常胶质细胞(购买自ScienCell,Carlsbad,CA)中，并分别在胶质瘤细胞系U87、U251、U373及正常胶质细胞中加入1000μM、100μM、10μM、1μM、0.1μM、0.01μM浓度梯度的前体药物更昔洛韦(ganciclovir，GCV)，分别在48h、72h、96h后通过CCK-8法检测U87、U251、U373及正常胶质细胞的数量，计算U87、U251、U373及正常胶质细胞的存活率(其检测结果如图4所示)。其中，图3示出了pDC315-CFOS-TK-IRES-hrGFP腺病毒感染胶质瘤细胞系U373的荧光图像。
由于实验验证了c-fos启动子在胶质瘤细胞中的转录活性仅次于CMV启动子，高于Tert、Survivin、E2F1、Cox2、Vector等启动子，因此，作为对照组，以同样的方法构建出包含CMV启动子的腺病毒重组表达载体——pDC315-CMV-TK-IRES-hrGFP，并对比研究其对胶质瘤细胞和正常胶质细胞的作用：
将腺病毒重组表达载体pDC315-CMV-TK-IRES-hrGFP转染293细胞，待细胞有出毒迹象时，收集病毒上清，利用病毒上清将病毒扩增至P3代，其后用ViraBind腺病毒纯化试剂盒纯化病毒，获得纯化浓缩的CMV/HSV-TK/miR-128腺病毒。
通过病毒扩增法使CMV/HSV-TK/miR-128腺病毒的滴度达到1×10^10PFU/ML；
以不同感染复数(MOI：100,10，1)的CMV/HSV-TK/miR-128腺病毒分别加入到胶质瘤细胞系U87、U251、U373及正常胶质细胞Astrocytes(购买自ScienCell,Carlsbad,CA)中，然后分别在胶质瘤细胞系U87、U251、U373及正常胶质细胞中加入1000μM、100μM、10μM、1μM、0.1μM、0.01μM浓度梯度的前体药物更昔洛韦(ganciclovir，GCV)，分别在48h、72h、96h后通过CCK-8法检测U87、U251、U373及正常胶质细胞的数量，计算U87、U251、U373及正常胶质细胞的存活率(检测结果见图4)。其中，图3示出了pDC315-CMV-TK-IRES-hrGFP腺病毒感染胶质瘤细胞系U373的荧光图像。
图4中，Ad-CMV代表CMV/HSV-TK/miR-128腺病毒，Ad-CFOS代表c-fos/HSV-TK/miR-128腺病毒。
根据图4可以看出，两种腺病毒都能抑制胶质瘤细胞，但是，CMV/HSV-TK/miR-128腺病毒对正常胶质细胞有杀伤作用，而c-fos/HSV-TK/miR-128腺病毒对正常胶质细胞无明显杀伤作用。
综上所述，c-fos/HSV-TK/miR-128腺病毒在胶质瘤细胞中可高效特异性的表达，其在正常细胞中转录活性低，其可提高自杀基因HSV-TK在胶质瘤细胞中的靶向性，并对自杀基因HSV-TK在正常细胞中的表达进行抑制，本发明的腺病毒对胶质瘤具有高度靶向特异性。
尽管通过以上实施例对本发明进行了揭示，但是本发明的范围并不局限于此，在不偏离本发明构思的条件下，以上各构件可用所属技术领域人员了解的相似或等同元件来替换。
Claims (8)
1.一种胶质瘤细胞中高效特异表达的自杀基因腺病毒，其特征在于，该腺病毒基因组中包含有c-fos启动子、自杀基因和在正常细胞高表达并在胶质瘤细胞中表达确实的miR-128的互补序列，所述自杀基因位于所述c-fos启动子的下游，所述miR-128的互补序列位于所述自杀基因的下游。
2.如权利要求1所述的胶质瘤细胞中高效特异表达的自杀基因腺病毒，其特征在于，所述腺病毒通过下述方法构建：
使用PCR方法克隆c-fos基因启动子片段，将其连接到腺病毒表达载体上，在c-fos启动子下游连接自杀基因及miR-128的互补序列，构建出腺病毒重组表达载体；将腺病毒重组表达载体转染293细胞，待细胞有出毒迹象时，收集病毒上清，并将病毒扩增至P3代，其后用腺病毒纯化试剂盒纯化病毒，以获得所述腺病毒。
3.如权利要求2所述的胶质瘤细胞中高效特异表达的自杀基因腺病毒，其特征在于，所述自杀基因为单纯疱疹病毒胸苷激酶HSV-TK，所述腺病毒表达载体为pDC315。
4.如权利要求3所述的胶质瘤细胞中高效特异表达的腺病毒，其特征在于，所述腺病毒纯化试剂盒选用ViraBind腺病毒纯化试剂盒。
5.如权利要求2所述的胶质瘤细胞中高效特异表达的自杀基因腺病毒，其特征在于，所述miR-128的互补序列通过以下方法确定：
使用PCR方法克隆不同片段长度的c-fos启动子片段，设计CMV增强子(IE)序列，优化启动子与多克隆位点(MCS)及表达框(ORF)的距离，设计出高效转录表达的表达框；
将表达框连接到pGL4表达载体上，克隆出pGL4-cfos重组表达载体；
通过miRBase数据库，设计若干条序列不同的miR-128的互补序列，并将其分别串联到pGL4-cfos重组表达载体的3’末端，构建出若干种序列不同的pGL4-cfos-miR128重组表达载体；
利用外源荧光素酶法检测各pGL4-cfos-miR128重组表达载体中的c-fos启动子在胶质瘤细胞和正常细胞中的转录水平，筛选出在胶质瘤细胞中具有较高转录水平而在正常细胞中具有较低转录水平的pGL4-cfos-miR128重组表达载体，将该pGL4-cfos-miR128重组表达载体所对应的miR-128的互补序列作为构建腺病毒重组表达载体所需的miR-128的互补序列。
6.一种腺病毒的构建方法，其特征在于，其包括以下步骤：
使用PCR方法克隆c-fos基因启动子片段，将其连接到腺病毒表达载体Pdc315上；
在c-fos启动子下游连接自杀基因及miR-128的互补序列，构建出腺病毒重组表达载体；
将腺病毒重组表达载体转染293细胞，待细胞有出毒迹象时，收集病毒上清，并将病毒扩增至P3代，其后用腺病毒纯化试剂盒纯化病毒，以获得所述腺病毒。
7.如权利要求6所述的腺病毒的构建方法，其特征在于，在c-fos启动子下游连接自杀基因及miR-128的互补序列，构建出腺病毒重组表达载体时，其还可将用于标记的绿色荧光蛋白基因GFP连接在c-fos启动子下游。
8.如权利要求6所述的腺病毒的构建方法，其特征在于，所述miR-128的互补序列通过以下方法确定：
使用PCR方法克隆不同片段长度的c-fos启动子片段，设计CMV增强子(IE)序列，优化启动子与多克隆位点(MCS)及表达框(ORF)的距离，设计出高效转录表达的表达框；
将表达框连接到pGL4表达载体上，克隆出pGL4-cfos重组表达载体；
通过miRBase数据库，设计若干条序列不同的miR-128的互补序列，并将其分别串联到pGL4-cfos重组表达载体的3’末端，构建出若干种序列不同的pGL4-cfos-miR128重组表达载体；
利用外源荧光素酶法检测各pGL4-cfos-miR128重组表达载体中的c-fos启动子在胶质瘤细胞和正常细胞中的转录水平，筛选出在胶质瘤细胞中具有较高转录水平而在正常细胞中具有较低转录水平的pGL4-cfos-miR128重组表达载体，将该pGL4-cfos-miR128重组表达载体所对应的miR-128的互补序列作为构建腺病毒重组表达载体所需的miR-128的互补序列。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911171025.7A CN110964747A (zh) | 2019-11-26 | 2019-11-26 | 胶质瘤细胞中高效特异表达的自杀基因腺病毒及构建方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911171025.7A CN110964747A (zh) | 2019-11-26 | 2019-11-26 | 胶质瘤细胞中高效特异表达的自杀基因腺病毒及构建方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110964747A true CN110964747A (zh) | 2020-04-07 |
Family
ID=70031626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911171025.7A Pending CN110964747A (zh) | 2019-11-26 | 2019-11-26 | 胶质瘤细胞中高效特异表达的自杀基因腺病毒及构建方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110964747A (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020042139A1 (en) * | 2000-05-31 | 2002-04-11 | Higginbotham James N. | Methods and compositions for efficient gene transfer using transcomplementary vectors |
| WO2002101076A2 (en) * | 2001-06-13 | 2002-12-19 | Eastern Virginia Medical School | Methods for targeted expression of therapeutic nucleic acid |
| US6537541B1 (en) * | 1990-09-14 | 2003-03-25 | The General Hospital Corporation | Implantation of HSV-TK retrovirus producer cells to destroy glioma |
| WO2009142602A1 (en) * | 2008-05-19 | 2009-11-26 | Agency For Science, Technology And Research | Nucleic acid molecule and method of targeting gene expression to gliomas |
| US20100143304A1 (en) * | 2007-01-30 | 2010-06-10 | Cedars-Sinai Medical Center | Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene |
-
2019
- 2019-11-26 CN CN201911171025.7A patent/CN110964747A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6537541B1 (en) * | 1990-09-14 | 2003-03-25 | The General Hospital Corporation | Implantation of HSV-TK retrovirus producer cells to destroy glioma |
| US20020042139A1 (en) * | 2000-05-31 | 2002-04-11 | Higginbotham James N. | Methods and compositions for efficient gene transfer using transcomplementary vectors |
| WO2002101076A2 (en) * | 2001-06-13 | 2002-12-19 | Eastern Virginia Medical School | Methods for targeted expression of therapeutic nucleic acid |
| US20100143304A1 (en) * | 2007-01-30 | 2010-06-10 | Cedars-Sinai Medical Center | Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene |
| WO2009142602A1 (en) * | 2008-05-19 | 2009-11-26 | Agency For Science, Technology And Research | Nucleic acid molecule and method of targeting gene expression to gliomas |
Non-Patent Citations (4)
| Title |
|---|
| CHUNXIAO WU 等: "Combinatorial Control of Suicide Gene Expression by Tissue-specific Promoter and microRNA Regulation for Cancer Therapy", 《MOLECULAR THERAPY》 * |
| REBECCA L. SKALSKY 等: "Reduced Expression of Brain-Enriched microRNAs in Glioblastomas Permits Targeted Regulation of a Cell Death Gene", 《PLOS ONE》 * |
| 王浩 等: "C-fos启动子在人胶质瘤细胞株及正常组织的转录活性研究", 《中华神经医学杂志》 * |
| 王浩 等: "腺病毒介导的HSV-TK/GCV系统在Cfos启动子调控下对胶质瘤细胞的杀伤作用", 《中华神经医学杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhao et al. | Viral vector‐based gene therapies in the clinic | |
| Pol et al. | Trial watch: oncolytic viruses for cancer therapy | |
| US7048920B2 (en) | Recombinant oncolytic adenovirus for human melanoma | |
| Cody et al. | Armed replicating adenoviruses for cancer virotherapy | |
| Deng et al. | Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9 | |
| Yao et al. | The application of multiple miRNA response elements enables oncolytic adenoviruses to possess specificity to glioma cells | |
| AU699867B2 (en) | Recombinant adenoviruses for gene therapy in cancers | |
| Delwar et al. | Tumour-specific triple-regulated oncolytic herpes virus to target glioma | |
| CN104178460A (zh) | 一种受转录和转录后双调控的溶瘤腺病毒及其构建方法 | |
| Hernandez-Alcoceba et al. | Gene therapy of liver cancer | |
| Shen et al. | Specific CEA-producing colorectal carcinoma cell killing with recombinant adenoviral vector containing cytosine deaminase gene | |
| Sutter et al. | Gene therapy for gastric cancer: is it promising? | |
| Hernández-Alcoceba et al. | Gene therapy of liver cancer | |
| CN110964747A (zh) | 胶质瘤细胞中高效特异表达的自杀基因腺病毒及构建方法 | |
| US20060275262A1 (en) | Conditionally replicating viruses and methods for cancer virotherapy | |
| JP2018516599A (ja) | ポックスウイルス由来のプロモーターおよびそれを含むベクター | |
| CN112011570A (zh) | 特异杀伤肿瘤细胞的溶瘤病毒系统及其应用 | |
| Kyritsis et al. | Viruses, gene therapy and stem cells for the treatment of human glioma | |
| Fu et al. | Potential adenovirus-mediated gene therapy of glioma cancer | |
| Kosmidis et al. | Gene therapy for hepatocellular carcinoma: An update | |
| US11235072B2 (en) | Adenovirus complex for gene delivery and gene iherapy | |
| CN101880688B (zh) | 一种使复制缺陷型腺病毒选择性复制的方法和用途 | |
| CN114703186B (zh) | 肿瘤特异性启动子及其应用 | |
| Lowenstein et al. | The basic science of brain-tumour gene therapy | |
| EP1156118A1 (en) | Virus vector |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200407 |
|
| RJ01 | Rejection of invention patent application after publication |